Ralph Weichselbaum to Survival Rate
This is a "connection" page, showing publications Ralph Weichselbaum has written about Survival Rate.
Connection Strength
0.963
-
The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014 09; 11(9):549-57.
Score: 0.076
-
The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy. Clin Lung Cancer. 2014 Sep; 15(5):365-71.
Score: 0.076
-
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141.
Score: 0.069
-
Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine. Mol Ther. 2012 May; 20(5):1046-55.
Score: 0.065
-
MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 2010 May 06; 3:16.
Score: 0.057
-
MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A. 2009 Apr 07; 106(14):5837-41.
Score: 0.053
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.032
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.030
-
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
Score: 0.029
-
Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res. 1999 Jun; 5(6):1517-22.
Score: 0.027
-
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Radiat Oncol. 2019 Jan 28; 14(1):18.
Score: 0.026
-
Breast preservation in stage I and II carcinoma of the breast. The University of Chicago experience. Cancer. 1996 Oct 15; 78(8):1722-30.
Score: 0.022
-
Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Rev Anticancer Ther. 2016 Jun; 16(6):625-32.
Score: 0.022
-
Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res. 1996 Apr; 2(4):755-62.
Score: 0.022
-
Patterns of Failure After Radical Cystectomy for pT3-4 Bladder Cancer: Implications for Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Apr 01; 94(5):1031-9.
Score: 0.021
-
Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015 Feb 01; 91(2):344-50.
Score: 0.020
-
Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme. Cancer Invest. 1995; 13(5):453-9.
Score: 0.020
-
Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2015 Jul; 22(7):2209-17.
Score: 0.020
-
Effect of postradiotherapy neck dissection on nonregional disease sites. JAMA Otolaryngol Head Neck Surg. 2014 Jan; 140(1):12-21.
Score: 0.018
-
EPR oxygen images predict tumor control by a 50% tumor control radiation dose. Cancer Res. 2013 Sep 01; 73(17):5328-35.
Score: 0.018
-
Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol. 2013 Jul; 8(7):915-22.
Score: 0.018
-
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol. 1992 Jun; 19(3 Suppl 9):53-8.
Score: 0.017
-
Prognostic indicators in node-negative early stage breast cancer. Am J Med. 1992 May; 92(5):539-48.
Score: 0.016
-
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
Score: 0.016
-
Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012 Mar; 107(1):207-12.
Score: 0.016
-
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 1991 Oct; 14(5):419-26.
Score: 0.016
-
Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J Clin Oncol. 1991 Aug; 9(8):1376-84.
Score: 0.016
-
Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol. 1991 Feb; 9(2):328-34.
Score: 0.015
-
Is pelvic irradiation necessary in stage III1A Hodgkin's disease? Int J Radiat Oncol Biol Phys. 1990 Sep; 19(3):715-9.
Score: 0.015
-
Radiation therapy in the treatment of cervical cancer: the University of Chicago/Michael Reese Hospital experience. J Surg Oncol. 1990 Jul; 44(3):157-65.
Score: 0.015
-
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
Score: 0.014
-
Breast conserving surgery and definitive irradiation for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1211-6.
Score: 0.014
-
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.012
-
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
Score: 0.009
-
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
Score: 0.009
-
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
Score: 0.009
-
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998 Aug; 16(8):2715-21.
Score: 0.006
-
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992 Jun; 102(6):630-6.
Score: 0.004
-
Prognostic factors in advanced head and neck cancer patients undergoing multimodality therapy. Otolaryngol Head Neck Surg. 1991 Jul; 105(1):62-73.
Score: 0.004